Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
National Center for Complementary and Alternative Medicine (NCCAM) Office of Dietary Supplements (ODS) |
---|---|
Information provided by: | National Center for Complementary and Alternative Medicine (NCCAM) |
ClinicalTrials.gov Identifier: | NCT00070941 |
This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).
Condition | Intervention | Phase |
---|---|---|
Parkinson's Disease Depression |
Drug: SAM-e Drug: oral citalopram Drug: placebo |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | SAM-e Treatment of Depression in Parkinson's Disease |
Estimated Enrollment: | 80 |
Study Start Date: | July 2003 |
Estimated Study Completion Date: | October 2008 |
Estimated Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
40 subjects receiving oral SAM-e, 1200mg or 1800mg daily in two divided doses, and placebo citalopram.
|
Drug: SAM-e
oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo citalopram.
|
2: Active Comparator
40 subjects receiving oral citalopram 20mg or 40 mg daily, in two divided doses, and placebo SAM-e.
|
Drug: oral citalopram
20mg or 30mg daily in two divided doses, along with placebo SAM-e.
|
3: Placebo Comparator
20 subjects receiving oral placebo citalopram and placebo SAM-3 daily in two divided doses.
|
Drug: placebo
oral placebo citalopram and oral placebo SAM-e daily in two divided doses.
|
PD is commonly associated with depression, but conventional antidepressants have limited efficacy in patients with PD and may exacerbate motor symptoms. SAM-e is available in the United States as a food supplement and is promoted as a mood enhancer. SAM-e improves dopamine transmission, may have a beneficial effect on dopamine receptors, and may be a good alternative to the currently-used antidepressants in patients with PD. This study will investigate whether SAM-e is safe and effective in the treatment of depression associated with PD. The efficacy of SAM-e will be compared to placebo and to escitalopram, a selective serotonin reuptake inhibitor commonly used for the treatment of depression in PD.
Participants in this study will be randomly assigned to receive SAM-e, escitalopram, or placebo for 12 weeks. Some participants may choose to extend treatment for an additional 12 weeks (for a total of 24 weeks on study medication). Participants will have study visits at entry and Weeks 2, 4, 8, and 12. Study visits will include neurological evaluation, psychiatric evaluation, blood tests, and quality of life questionnaires. A telephone interview will be conducted at Week 10.
Ages Eligible for Study: | 30 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
United States, New York | |
New York University | Recruiting |
New York, New York, United States, 10003 | |
Contact: Alessandro DiRocco, MD alessandro.dirocco@med.nyu.edu | |
Principal Investigator: Alessandro Di Rocco, MD |
Principal Investigator: | Alessandro Di Rocco, MD | NYU |
Responsible Party: | NYU School of Medicine ( Alessandro Di Rocco, MD Chief, Division of Movement Disorders, Department of Neurology ) |
Study ID Numbers: | R01 AT000941-01A1 |
Study First Received: | October 9, 2003 |
Last Updated: | August 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00070941 |
Health Authority: | United States: Federal Government |
Parkinsons Disease Depression SAM-e |
Depression Ganglion Cysts Basal Ganglia Diseases Central Nervous System Diseases Depressive Disorder Brain Diseases Neurodegenerative Diseases Citalopram |
Serotonin Behavioral Symptoms Parkinson Disease Mental Disorders Movement Disorders Mood Disorders Parkinsonian Disorders Dexetimide |
Parasympatholytics Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Cholinergic Antagonists Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Antiparkinson Agents Cholinergic Agents |
Serotonin Uptake Inhibitors Pharmacologic Actions Muscarinic Antagonists Serotonin Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |